First‑Line Pharmacologic Management of Persistent Depressive Disorder

Guideline Recommendations

The American College of Physicians guideline explicitly addresses dysthymia as a target condition for second-generation antidepressant therapy, establishing that these medications are appropriate for treating this chronic depressive disorder 4, 5, 6, 7
The American College of Physicians recommends second-generation antidepressants (SSRIs, SNRIs) as the preferred first-line pharmacologic treatment for dysthymia, with all second-generation antidepressants showing similar efficacy for depressive symptoms 4, 8, 6

The selection of second-generation antidepressants should be based primarily on side effect profile and tolerability, as well as patient-specific factors, including comorbidities, prior medication responses, and drug interactions, with bupropion having the lowest risk of sexual side effects among antidepressants 9

The American College of Physicians notes that for patients with 2 or more depressive episodes, continuing treatment for at least 2 years as prophylactic therapy may be beneficial, and even longer duration may be necessary 8

Assess patient status within 1-2 weeks of initiation and continue regular monitoring throughout treatment for therapeutic response and adverse effects, including monitoring closely for suicidality, particularly in young adults 9
When discontinuing, taper gradually over a minimum of 10-14 days to avoid withdrawal symptoms 9

Weak evidence suggests SNRIs may be associated with increased cardiovascular events, so consider this in patients with cardiac risk factors 9